The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation

Eva Segelov; Kate Wilson; Val Gebski; Paul Waring; Jayesh Desai; Louise Nott; Christos Karapetis; Harpreet Wasan; Jeremy Shapiro

The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation

Eva Segelov, Kate Wilson, Val Gebski, Paul Waring, Jayesh Desai, Louise Nott, Christos Karapetis, Harpreet Wasan, Jeremy Shapiro

Research output: Contribution to conference › Poster

Original language	English
Pages	155
Number of pages	1
Publication status	Published - 2013
Externally published	Yes

1 Abstract

The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.
Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Mann, K., Elez, M. E., Chantrill, L. A., Pavlakis, N., Nott, L., Underhill, C., Khasraw, M., Wasan, H., Ciardiello, F., Jefford, M. J., Joubert, W., Haydon, A. M. M., Karapetis, C., Price, T. J., Wilson, K. & Shapiro, J., 2015, p. S726. 1 p.
Research output: Contribution to conference › Abstract

Cite this

@conference{e174f78dfcee4884bc4e229864bcf0ee,

title = "The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation",

author = "Eva Segelov and Kate Wilson and Val Gebski and Paul Waring and Jayesh Desai and Louise Nott and Christos Karapetis and Harpreet Wasan and Jeremy Shapiro",

year = "2013",

language = "English",

pages = "155",

}

TY - CONF

T1 - The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation

AU - Segelov, Eva

AU - Wilson, Kate

AU - Gebski, Val

AU - Waring, Paul

AU - Desai, Jayesh

AU - Nott, Louise

AU - Karapetis, Christos

AU - Wasan, Harpreet

AU - Shapiro, Jeremy

PY - 2013

Y1 - 2013

M3 - Poster

SP - 155

ER -

The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation

Research output

The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.

Cite this